Table 3.
Adverse event recurrence, bosutinib dose modifications, and cross-intolerance in patients with prior dasatinib intolerance.*
Official websites use .gov
A
.gov website belongs to an official
government organization in the United States.
Secure .gov websites use HTTPS
A lock (
) or https:// means you've safely
connected to the .gov website. Share sensitive
information only on official, secure websites.